Leucine nitrate

Leucine Nitrate

1. Identity and Chemical Description

Leucine nitrate (also rendered as L-leucine nitrate) is a synthetic ionic salt formed by combining the essential branched-chain amino acid L-leucine with the nitrate anion (NO₃⁻). It is catalogued in the PubChem chemical database under CID 25232630 with the molecular formula C₆H₁₄N₂O₅. This formula reflects the protonated leucine cation (L-leucinium, C₆H₁₄NO₂⁺) paired electrostatically with the nitrate anion (NO₃⁻).

Leucine (symbol Leu or L) is an essential amino acid used in the biosynthesis of proteins. It is an α-amino acid containing an α-amino group, an α-carboxylic acid group, and a side chain isobutyl group, making it a non-polar aliphatic amino acid. It is essential in humans and animals, meaning the body cannot synthesize it and it must be obtained from the diet. Human dietary sources include foods that contain protein, such as meats, dairy products, soy products, and beans and other legumes.

Leucine nitrate is not a naturally occurring compound. It is produced semi-synthetically by pairing purified L-leucine with a nitrate counter-ion. Applicants in the relevant patent literature describe the synthesis of leucine nitrate by combining nitric acid and leucine, mixing with water or another polar, easily evaporated solvent such as methanol, alcohol, or pyridine, and leaving the mixture to crystallize. Further nitratization can take place, yielding leucine dinitrate or leucine trinitrate. An alternative implementation substitutes the amino acids valine or isoleucine for leucine. Another alternative substitutes nitrous acid (HNO₂) for nitric acid (HNO₃), yielding leucine nitrite; leucine nitrite is described as having the same effects as leucine nitrate, the only difference being that it requires one less step to yield nitric oxide (NO).

Mixed salts may also be used, such as leucine nitrate-orotate. The parent L-leucine used as the amino acid starting material may be derived from fermentation processes; commercially, a fermented vegan form of L-leucine nitrate has appeared in the ingredient supply market.

2. Common Forms and Preparations

In the dietary supplement context, leucine nitrate is encountered principally in the following forms:

• Crystalline powder: The direct product of the acid-base reaction and crystallization procedure, suitable for encapsulation or dissolution in liquid products.
• Pre-workout blends: Patent filings describe a method of producing an amino acid and nitrate supplement drink suitable for human consumption by adding water to the solid nitrate salt; leucine nitrate is enumerated alongside creatine nitrate, arginine nitrate, and related compounds in the class of amino acid nitrate salts.
• Mixed-salt and orotate forms: Leucine nitrate-orotate is cited as a variant providing a second organic counter-ion.
• Leucine nitrite: An analogous salt providing the nitrite anion rather than nitrate, described as functionally related but with a shorter metabolic conversion path to nitric oxide.

Amino acid salts with inorganic acids are described as being much more water-soluble than single administration amino acids; leucine nitrate is likewise described as being more water-soluble than single-administration leucine. This improved solubility is presented in the patent literature as a formulation advantage for beverage applications.

3. Traditional and Historical Use

Leucine nitrate as a defined chemical entity has no documented history of traditional or historical use in any ethnobotanical, Ayurvedic, Traditional Chinese Medicine, or other traditional medicine system. The compound does not arise from plant sources or fermentation products used historically; it is a product of synthetic organic chemistry and was first described in the context of modern dietary supplement patent applications.

The two constituent moieties, however, have separate historical contexts. L-Leucine is a dietary amino acid that has been consumed throughout human history as a component of protein-containing foods. Human dietary sources of leucine include foods that contain protein, such as meats, dairy products, soy products, and beans and other legumes. Dietary nitrate, present in vegetables such as spinach and beetroot, similarly has been consumed as a food component throughout history, though its specific physiological role in nitric oxide biology was not understood until the late twentieth and early twenty-first centuries.

The concept of combining an amino acid with a nitrate counter-ion appears as a distinctly modern innovation, arising from sports nutrition formulation research in the early twenty-first century. No pre-modern traditional preparation of leucine nitrate as such has been identified in the available literature.

4. Key Constituents and Active Compounds

Because leucine nitrate is itself a simple ionic salt, its pharmacological and nutritional activities are understood through the behavior of its two constituent ions upon dissociation and absorption: L-leucine and the nitrate anion (NO₃⁻).

4.1 L-Leucine

Ingestion of a leucine-enriched essential amino acid nutrient solution rapidly and potently activates the mammalian target of rapamycin (mTOR) signalling pathway and protein synthesis in human skeletal muscle. Further, mTOR signalling and muscle protein synthesis are enhanced when leucine-enriched nutrients are ingested following resistance exercise.

In vitro investigations in HeLa cells have identified a leucine-specific mechanism of mTORC1 activation whereby leucine binding with Sestrin proteins leads to the activation of Rag proteins at the lysosomal membrane and subsequent recruitment of mTORC1 to these areas. These findings have since been replicated in skeletal muscle both in vitro and in vivo, observing mTORC1 activation following leucine administration or ingestion alone.

The main function of mTORC1 is to regulate mRNA translation by directly phosphorylating two downstream substrates, ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor (eIF) 4E-binding protein-1 (4E-BP1). mTORC1 signalling also enhances muscle mass in part by blocking autophagy, a catabolic process that breaks down the protein reservoir if amino acid supply is not maintained. Protein degradation via the proteasome is also activated when leucine levels become low.

Animal experiments using the mTOR inhibitor rapamycin demonstrated that rapamycin completely blocked leucine-induced muscle protein synthesis in neonatal piglets infused with leucine, confirming that mTORC1 is the principal mediator of this anabolic signal.

4.2 The Nitrate Anion and the Nitrate–Nitrite–Nitric Oxide Pathway

Nitric oxide (NO) is a pleiotropic signalling molecule involved in regulating skeletal muscle physiology, including blood flow, contractility, and metabolism. For decades, the synthesis of NO was attributed solely to L-arginine-dependent nitric oxide synthase (NOS) enzymes. However, the discovery and characterization of the nitrate–nitrite–NO pathway has revealed an alternative, NOS-independent mechanism for NO generation.

In the enterosalivary nitrate circulation, or nitrate-nitrite-NO pathway, dietary nitrate is swallowed and rapidly absorbed in the proximal gastrointestinal tract. In proportion to the dietary load of nitrate, approximately 25% of total circulating nitrate is actively sequestered into salivary glands and concentrated in saliva up to 20 times that in plasma.

Formation of nitrite and propagation of its downstream NO-signalling effects depends on the oral bacterial reduction of inorganic nitrate by a set of bacterial nitrate reductase enzymes (NaRs) that are largely absent from the human genome. In this pathway, dietary nitrate, as well as nitrate entering the oral cavity through the enterosalivary circulation, is reduced to nitrite by nitrate reductases expressed in commensal oral bacteria. Nitrite is a relatively stable vascular reserve of NO, with NO produced by this pathway exerting similar functions to those described for eNOS-derived NO.

In conditions of cardiovascular dysfunction, NOS activity is impaired, leading to NO deficiency. The reduction in NO bioactivity exacerbates the pathogenesis of cardiovascular diseases. Exogenous intake of inorganic nitrate supplements endogenous production via the nitrate–nitrite–NO pathway to maintain the NO supply.

This pathway is particularly significant under hypoxic and acidic conditions, which are characteristic of exercising skeletal muscle.

4.3 The Rationale for Combining Both Moieties

The patent literature contends that the leucine nitrate compound, when ingested, provides enhanced nitric oxide production while providing improved vasodilation effects over single administration of leucine, the single administration of nitrates, or the single administration of nitrites. Improved vasodilation may, in turn, provide better circulation and distribution of leucine in the body. Additionally, a much lesser dose may be required for vasodilation to take place compared to the single administration of nitrates.

It is important to note that these rationales are described in patent applications — a category of literature that does not constitute peer-reviewed clinical evidence. As of the available literature, no independent, peer-reviewed human clinical trial has tested leucine nitrate as a distinct compound to validate these claims.

5. Scientific Evidence by Area of Use

A critical preliminary note: No peer-reviewed human clinical trial identified in the available literature has specifically studied leucine nitrate as a standalone compound. The scientific evidence below therefore necessarily draws on the independent research bodies for L-leucine and for inorganic dietary nitrate separately. Extrapolating from constituent research to the salt form requires caution and represents inference, not established fact for leucine nitrate itself.

5.1 Skeletal Muscle Protein Synthesis and Anabolism

Evidence for L-Leucine (human clinical):

The addition of leucine to regular meals may improve the ability of feeding to stimulate protein synthesis in older human muscle. Leucine and essential amino acids appear to stimulate human muscle protein synthesis primarily by activating the mTOR signalling pathway, although how human muscle cells sense an increase in leucine to activate mTOR signalling is currently unknown.

As a dietary supplement, leucine has been found to slow the degradation of muscle tissue by increasing the synthesis of muscle proteins in aged rats. However, results of comparative studies are conflicted, and long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men.

Evidence strength: Preliminary-to-moderate for specific effects on muscle protein synthesis markers; weak-to-mixed for hard clinical outcomes (muscle mass, strength) in isolation, particularly in the elderly.

5.2 Sarcopenia (Age-Related Muscle Loss)

A placebo-controlled, randomized, double-blind trial enrolled fifty participants aged 65 and over, randomized to a 13-week parallel intervention with a daily intake of leucine (6 g/day) or placebo (lactose, 6 g/day). Administration of leucine was well-tolerated and significantly improved some criteria of sarcopenia in elderly individuals, including functional performance measured by walking time (p = 0.011) and improved lean mass index. The leucine-treated group improved significantly (p = 0.026) in maximum static expiratory force compared to placebo. No significant effects on functional impairment, cognitive function, nutritional assessment, or inflammatory cytokines IL-6 and TNF-alpha were observed.

A 2022 systematic review and meta-analysis of 17 randomized controlled trials addressed leucine's effects on sarcopenia. Leucine-isolated supplementation showed no effect on total lean mass (WMD = 0.03 kg, 95% CI: –0.51, 0.57, P = 0.917), handgrip strength (WMD = 1.23 kg, 95% CI: –0.58, 3.03, P = 0.183), or leg press (WMD = –1.35 kg, 95% CI: –7.46, 4.77, P = 0.666). However, leucine-combined supplementation including vitamin D showed a significant improvement in handgrip strength (WMD = 2.17 kg, 95% CI: 0.24, 4.10, P = 0.027) and gait speed (WMD = 0.03 m/s, 95% CI: 0.01, 0.05, P = 0.008). The conclusion was that leucine-isolated supplementation did not improve muscle mass and strength in the elderly, but leucine combined with vitamin D exhibited significant benefit for muscle strength and performance.

Evidence strength: Moderate for functional performance outcomes with leucine at 6 g/day in a single RCT; the meta-analytic evidence for isolated leucine on mass and strength is negative; combination with other nutrients may be necessary for meaningful benefit.

5.3 Exercise Performance and Athletic Endurance

Research on dietary nitrate as a contributor to exercise performance is more extensive than that on leucine for the same purpose. Dietary nitrate is known to dilate blood vessels and lower blood pressure by contributing to nitric oxide production. It has also been established that dietary nitrate can improve exercise performance, reduce muscle fatigue, and optimize oxygen consumption.

Research has demonstrated that dietary nitrate (NO₃⁻), as a source of nitric oxide via the reduction of NO₃⁻ to nitrite (NO₂⁻) and subsequently to NO, can significantly enhance muscle speed and power in various subject populations, including healthy young and middle-aged individuals, athletes, and patients with heart failure. The exact mechanisms responsible for this effect are still uncertain, but appear to involve NO-mediated changes in muscle calcium (Ca²⁺) release and/or sensitivity.

Previous research indicates that nitrate supplementation is less effective in well-trained individuals with VO₂max greater than 65 mL/kg/min.

Evidence strength for nitrate on exercise performance: Moderate; several human studies show benefit in less-trained individuals, but evidence is less consistent in highly trained athletes. Evidence that leucine nitrate specifically produces these outcomes is absent.

5.4 Cardiovascular and Blood Pressure Effects

The enterosalivary nitrate–nitrite–NO pathway improves mitochondrial activity, regulates Ca²⁺ handling, lowers blood pressure, protects against heart failure and ischemia-reperfusion injury, and preserves endothelial cell function.

In conditions of impaired NO synthase (NOS)-dependent NO generation such as obesity and endothelial dysfunction, the entero-salivary nitrate-nitrite-NO pathway may serve as a backup system for NO generation, transmitting NO activities in various molecular forms including NO and protein S-nitrosothiols. Evidence has demonstrated that dietary intake of fruits and vegetables rich in nitrate/nitrite is an inexpensive and easily practicable way to prevent insulin resistance and vascular endothelial dysfunction by increasing NO availability; a NO-rich diet may also prevent other lifestyle-related diseases, including osteoporosis, chronic obstructive pulmonary disease (COPD), and cancer.

Nitric oxide is essential in multiple physiological processes, and a reduction in nitric oxide bioavailability is associated with the occurrence or worsening of pathologies such as atherosclerosis, diabetes, and sepsis.

Evidence strength: Moderate for dietary nitrate on blood pressure and vascular function; this evidence pertains to the nitrate component and does not reflect studies of leucine nitrate specifically.

5.5 Nitric Oxide Boosting vs. L-Arginine Approaches

The rationale for amino acid nitrate salts in sports nutrition in part rests on perceived limitations of the conventional L-arginine approach. Nitric oxide and pre-workout nitric oxide performance enhancing formulas have grown in popularity. Such formulas are used to increase muscular "pumps," vasodilation, and nutrient transport to muscle to assist in greater aerobic performance and recovery. However, most formulas utilize the amino acid L-arginine, a precursor to nitric oxide, as their base. Clinical research confirms that the reduction of inorganic nitrate (NO₃⁻) and nitrite (NO₂⁻) in vivo results in NO production. Not only does nitrate generate NO, but nitrate and nitrite are inert end-products of NO oxidation — that is, nitrate converts into NO, and once oxidized, NO is recycled back into nitrate, which then has the potential to convert into NO once again.

The molecule 2-(nitroxy)ethyl 2-amino-3-methylbutanoate (a valine-ester nitrate) has been recognized to increase the delivery of NO in the human body and is considered to be more effective and efficient than other traditional NO donors. This is a structurally analogous but distinct compound from leucine nitrate.

Evidence strength: The mechanistic logic is well-supported; however, direct clinical evidence for leucine nitrate as an NO booster in humans has not been published in peer-reviewed literature as of available sources.

5.6 Muscle Power in Older Adults

Dietary nitrate has been shown to significantly enhance muscle speed and power in various subject populations, including healthy young and middle-aged individuals, athletes, and patients with heart failure. Acute NO₃⁻ ingestion also significantly improves muscle speed and power in healthy elderly subjects.

Combining this with the established role of leucine as an anabolic signal provides a theoretical basis for leucine nitrate's potential relevance to muscle function in older adults, but this remains speculative until leucine nitrate itself is directly tested in this population.

6. Body Systems and Health Areas of Association

Based on the established science of its constituent moieties, leucine nitrate is associated with the following body systems and health areas:

• Skeletal muscle system: Leucine's role as a trigger of mTORC1-mediated protein synthesis is the most extensively documented biological function. Ingestion of leucine-enriched nutrients rapidly and potently activates the mTOR signalling pathway and protein synthesis in human skeletal muscle.
• Cardiovascular system: Nitric oxide is a vasodilator that regulates vascular tension; endogenous NO is produced via the L-arginine–nitric oxide synthase (NOS) pathway. The nitrate component of leucine nitrate participates in this system through the enterosalivary cycle.
• Vascular endothelium: In conditions of cardiovascular dysfunction, NOS activity is impaired, leading to NO deficiency, and the reduction in NO bioactivity exacerbates the pathogenesis of cardiovascular diseases. Dietary nitrate supplementation addresses this via an alternative pathway.
• Metabolic and endocrine system: Leucine has documented roles in insulin signalling, glucose metabolism, and energy homeostasis. Evidence suggests that dietary intake of nitrate/nitrite may help prevent insulin resistance and vascular endothelial dysfunction by increasing NO availability.
• Respiratory muscle: In the sarcopenia RCT noted above, the leucine-treated group improved significantly in maximum static expiratory force compared to placebo.
• Oral microbiome and enterosalivary axis: The formation of nitrite and propagation of downstream NO-signalling effects depends on the oral bacterial reduction of inorganic nitrate by bacterial nitrate reductase enzymes. The health of the oral microbiome is therefore a significant moderator of the nitrate component's activity.

7. Dosage Forms and Dosages Reported in Sources

No clinical dosage data exist specifically for leucine nitrate as a standalone compound in the peer-reviewed literature. The following dosages are drawn from studies of the individual constituent moieties and from patent-derived descriptions; they are reported here exactly as found in those sources.

7.1 L-Leucine Dosages (from clinical studies)

• In a 13-week, placebo-controlled RCT in individuals aged 65 and over, the daily intake was leucine 6 g/day, administered orally.
• In another study, healthy elderly men were supplemented with 2.5 g of leucine at each main meal (i.e., approximately 7.5 g/day) for a period of 3 months without any reported adverse effects.
• One RCT in older adults with sarcopenia used protein supplementation including 11 g of protein and 2.3 g of leucine over 24 weeks.
• The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine set a Recommended Dietary Allowance for leucine, for adults 19 years and older, of 42 mg/kg body weight/day.

7.2 Dietary Nitrate Dosages (from clinical studies)

• Following ingestion of dietary nitrate, nitrate is rapidly absorbed in the upper gastrointestinal tract, leading to a peak in plasma concentration after 1–2 hours. Specific dosing protocols in performance studies have generally used beetroot juice or sodium nitrate providing approximately 6.4–12.8 mmol of nitrate per dose, though specific amounts vary across studies.

7.3 Formulation Notes from Patent Sources

• Patent claims describe a method of safely administering a nitrate with a reduced side effect comprising combining a quantity of an inorganic nitrate with a quantity of an amino acid compound to produce an amino acid nitrate salt, wherein the quantity of the amino acid compound is at least the quantity of the inorganic nitrate.
• The patent literature states that a much lesser dose may be required for vasodilation when using amino acid nitrate forms compared to single administration of nitrates.

8. Safety Considerations and Interactions

Safety data for leucine nitrate as a specific compound are not available from independent peer-reviewed studies. The following information is drawn from established safety data for L-leucine and inorganic dietary nitrate separately.

8.1 Safety of L-Leucine

No consistent evidence of toxicity has been linked to leucine supplements. In healthy subjects, no adverse events have been reported by subjects consuming oral leucine for a 6-week period. In another study, healthy elderly men were supplemented with 2.5 g of leucine at each main meal for a period of 3 months without any reported adverse effects. It has been reported that no adverse effects are associated with repeated oral administration of up to 60 g/day of BCAAs (providing 24 g/day of leucine) in patients with bipolar disorder. The body of evidence on oral administration of leucine in humans indicates that it can be consumed in considerable amounts without adverse effects. There are no dose-limiting toxicities known with oral leucine, and there is no defined Maximum Tolerated Dose.

The L-amino acids are considered Generally Recognized As Safe (GRAS) as direct food additives by the FDA.

Leucine, when consumed as a dietary supplement at high doses (greater than 500 mg/kg/day), has been associated with an increase in blood ammonia levels. While it is unlikely that doses employed in typical supplement contexts are adequate to elevate blood ammonia levels, the potential for synergism between leucine, metformin, and sildenafil has been noted.

8.2 Safety of the Nitrate Component

Patent claims related to amino acid nitrate salts specifically describe a method of safely administering a nitrate with reduced side effects, where the potential side effects of inorganic nitrate include nausea, gastric distress, gastric ulcer, diarrhea, abdominal pain, and methemoglobinemia. The claimed mechanism by which amino acid conjugation reduces these effects is presented in the patent applications and has not been independently validated in peer-reviewed human trials.

Because the plasma levels of nitrite are highly dependent on the amount of salivary nitrate and its reduction to nitrite, the use of an antibacterial mouthwash and frequent spitting of saliva consequently decrease the plasma levels of nitrite. This is a relevant practical consideration: the use of antiseptic oral rinses can substantially blunt the biological activity of the nitrate component of leucine nitrate.

8.3 Potential Interactions

The nitrate component of leucine nitrate is pharmacologically distinct from the organic nitrate medications (e.g., nitroglycerin, isosorbide mononitrate) used in cardiovascular therapy, which exert rapid, high-potency vasodilatory effects through direct nitric oxide donation. The nitrate anion in leucine nitrate functions through the enterosalivary reduction pathway, with a slower and more diffuse effect on NO production. Nonetheless, individuals taking phosphodiesterase-5 (PDE5) inhibitors or other vasodilatory agents should be aware that any nitrate-mediated enhancement of NO signalling could theoretically be additive. No specific clinical interaction studies for leucine nitrate have been conducted.

One study tested the hypothesis that elevated L-leucine concentrations in plasma reduce nitric oxide (NO) synthesis by endothelial cells and affect adiposity in obese rats, suggesting a potentially complex and bidirectional relationship between leucine and NO metabolism that may be context-dependent and requires further investigation in humans.

A potential exists for leucine to magnify the hypoglycemic effects of metformin, based on shared metabolic pathways; this interaction has been noted in clinical trial documentation and is relevant when leucine-containing supplements are combined with anti-diabetic medications.

8.4 Regulatory Status

As of the available literature, leucine nitrate does not have an established monograph in the United States Pharmacopeia, European Pharmacopoeia, WHO, EFSA, or ESCOP. It is a novel ingredient without a long history of use and without an EFSA or FDA safety opinion specifically addressing the salt form. Its constituent amino acid (L-leucine) is GRAS as a food additive, and dietary nitrate from food sources is broadly recognized as safe at normal dietary intakes, but these designations do not automatically extend to the specific salt combination.

9. Summary of Evidence Quality

The following table summarizes the evidence quality for claims commonly associated with leucine nitrate:

• L-Leucine activation of mTORC1 in muscle (mechanistic): Well-established at the molecular level in animal and cell models; confirmed in humans for signalling biomarkers.
• L-Leucine improving functional outcomes in sarcopenia (human RCT): Moderate evidence from a small number of RCTs; meta-analytic evidence for isolated leucine on mass and strength is negative; combination with vitamin D shows positive signals.
• Dietary nitrate reducing blood pressure and improving vascular function: Moderate-to-strong human evidence, primarily from beetroot juice studies.
• Dietary nitrate improving exercise performance: Moderate evidence in recreationally active individuals; weaker evidence in highly trained athletes.
• Leucine nitrate as a combined compound providing superior benefits vs. its components alone: No peer-reviewed clinical evidence; claims reside solely in patent applications.
• Safety of leucine nitrate at supplement doses: No dedicated human safety studies; inferred from established safety records of L-leucine and dietary nitrate separately.

References

• PubChem. l-Leucine nitrate | C6H14N2O5 | CID 25232630. National Institutes of Health.
• Wikipedia. Leucine. (citing Food and Nutrition Board, Institute of Medicine data)
• USPTO Patent 10,646,508. Method of safely administering nitrate dietary supplements and compositions.
• USPTO Patent 12,448,357. Amino acid compositions.
• USPTO Patent 10,426,792. Amino acid compositions.
• USPTO Patent 11,166,979. Amino acid compositions.
• USPTO Patent 12,473,261. Amino acid compositions.
• USPTO Patent 11,155,524. Amino acid compositions (supplement drink method).
• USPTO Patent 11,260,039. Amino acid compositions.
• USPTO Patent 10,894,025. Amino acid compositions.
• USPTO Patent 12,227,483. Amino acid compositions.
• Drummond MJ, Rasmussen BB. Leucine-Enriched Nutrients and the Regulation of mTOR Signalling and Human Skeletal Muscle Protein Synthesis. Current Opinion in Clinical Nutrition and Metabolic Care. PMC5096790.
• Norton LE, Layman DK. Leucine and mTORC1: a complex relationship. American Journal of Physiology-Endocrinology and Metabolism. 2011.
• Suryawan A, et al. Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. PMC2575905.
• Churchward-Venne TA, et al. Leucine-enriched amino acids maintain peripheral mTOR-Rheb localization independent of myofibrillar protein synthesis and mTORC1 signaling postexercise. PMC7469228.
• Davis TA, et al. Differential regulation of protein synthesis in skeletal muscle and liver of neonatal pigs by leucine through an mTORC1-dependent pathway. PMC3366465.
• Ispoglou T, et al. Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial. Nutrients. 2020. PMC7230494.
• Wu H, et al. The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials. Frontiers in Nutrition. 2022. PMC9284268.
• Luo Y, et al. Salivary-Gland-Mediated Nitrate Recirculation as a Modulator for Cardiovascular Diseases. PMC11940199.
• Machha A, Schechter AN. NO-Rich Diet for Lifestyle-Related Diseases. PMC4488823.
• Rocha BS, et al. Enterosalivary nitrate metabolism and the microbiome: intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. PMC5401802.
• Pelletier JM, et al. Antiseptic mouthwash, the nitrate–nitrite–nitric oxide pathway, and hospital mortality: a hypothesis generating review. PMC7567004.
• Pathways Linking Oral Bacteria, Nitric Oxide Metabolism, and Health. PMC9124908.
• Whitfield J, et al. The chemistry of the nitrate–nitrite–nitric oxide pathway: regulating muscle oxygenation and exercise performance. RSC Advances. 2026.
• Coggan AR, et al. Dose-response effect of dietary nitrate on muscle contractility and blood pressure in older subjects. medRxiv. 2020.
• Rathod KS, et al. Dietary supplements for improving nitric-oxide synthesis. PMC9710401.
• Šmid L, et al. The Effects of Nitrate Supplementation on Performance as a Function of Habitual Dietary Intake of Nitrates. Nutrients. 2023.
• Dündar A, et al. Investigation of the effect of nitrate and L-arginine intake on aerobic, anaerobic performance, balance, agility, and recovery in elite taekwondo athletes. PMC11703352.
• Dietary supplementation with L-leucine reduces nitric oxide synthesis by endothelial cells of rats. PubMed 37837386.
• Cosmetic Ingredient Review Expert Panel. Safety Assessment of α-Amino Acids as Used in Cosmetics. 2012.
• ClinicalTrials.gov NCT01362595. Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia. Protocol documentation.
• ClinicalTrials.gov NCT03364335. The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity. Protocol documentation (Leucine Toxicity section).
• Enhancing Muscle Quality: Exploring Leucine and Whey Protein in Sarcopenic Individuals. PMC12426612.
• Witham MD, et al. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. PMC5753568.
• Role of oral and gut microbiomes in enterosalivary nitrate metabolism and their effects on systemic disease. PMC12267184.